229 related articles for article (PubMed ID: 28789525)
1. Direct Loading of iTEP-Delivered CTL Epitope onto MHC Class I Complexes on the Dendritic Cell Surface.
Dong S; Wang P; Zhao P; Chen M
Mol Pharm; 2017 Oct; 14(10):3312-3321. PubMed ID: 28789525
[TBL] [Abstract][Full Text] [Related]
2. Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo.
Wang P; Dong S; Zhao P; He X; Chen M
Biomaterials; 2018 Nov; 182():92-103. PubMed ID: 30107273
[TBL] [Abstract][Full Text] [Related]
3. Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.
Dong S; Xu T; Wang P; Zhao P; Chen M
Acta Pharmacol Sin; 2017 Jun; 38(6):914-923. PubMed ID: 28414197
[TBL] [Abstract][Full Text] [Related]
4. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
5. An Albumin-binding Polypeptide Both Targets Cytotoxic T Lymphocyte Vaccines to Lymph Nodes and Boosts Vaccine Presentation by Dendritic Cells.
Wang P; Zhao P; Dong S; Xu T; He X; Chen M
Theranostics; 2018; 8(1):223-236. PubMed ID: 29290804
[No Abstract] [Full Text] [Related]
6. A Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers.
Dong S; Xu T; Zhao P; Parent KN; Chen M
Theranostics; 2016; 6(5):666-78. PubMed ID: 27022414
[TBL] [Abstract][Full Text] [Related]
7. Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers.
Cho S; Dong S; Parent KN; Chen M
J Drug Target; 2016; 24(4):328-39. PubMed ID: 26307138
[TBL] [Abstract][Full Text] [Related]
8. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous cognate epitope recognition by bovine CD4 and CD8 T cells is essential for primary expansion of antigen-specific cytotoxic T-cells following ex vivo stimulation with a candidate Mycobacterium avium subsp. paratuberculosis peptide vaccine.
Abdellrazeq GS; Fry LM; Elnaggar MM; Bannantine JP; Schneider DA; Chamberlin WM; Mahmoud AHA; Park KT; Hulubei V; Davis WC
Vaccine; 2020 Feb; 38(8):2016-2025. PubMed ID: 31902643
[TBL] [Abstract][Full Text] [Related]
10. Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity.
Dong S; Subramanian S; Parent KN; Chen M
J Control Release; 2020 Dec; 328():653-664. PubMed ID: 32961248
[TBL] [Abstract][Full Text] [Related]
11. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
[TBL] [Abstract][Full Text] [Related]
12. A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae.
Pinchuk I; Starcher BC; Livingston B; Tvninnereim A; Wu S; Appella E; Sidney J; Sette A; Wizel B
J Immunol; 2005 May; 174(9):5729-39. PubMed ID: 15843575
[TBL] [Abstract][Full Text] [Related]
13. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.
Ma W; Smith T; Bogin V; Zhang Y; Ozkan C; Ozkan M; Hayden M; Schroter S; Carrier E; Messmer D; Kumar V; Minev B
J Transl Med; 2011 Mar; 9():34. PubMed ID: 21450109
[TBL] [Abstract][Full Text] [Related]
14. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming.
Schlecht G; Loucka J; Najar H; Sebo P; Leclerc C
J Immunol; 2004 Nov; 173(10):6089-97. PubMed ID: 15528345
[TBL] [Abstract][Full Text] [Related]
15. Liposomal delivery of CTL epitopes to dendritic cells.
Chikh G; Schutze-Redelmeier MP
Biosci Rep; 2002 Apr; 22(2):339-53. PubMed ID: 12428909
[TBL] [Abstract][Full Text] [Related]
16. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
17. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus.
Hiranuma K; Tamaki S; Nishimura Y; Kusuki S; Isogawa M; Kim G; Kaito M; Kuribayashi K; Adachi Y; Yasutomi Y
J Gen Virol; 1999 Jan; 80 ( Pt 1)():187-193. PubMed ID: 9934701
[TBL] [Abstract][Full Text] [Related]
18. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
19. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice.
Dakappagari NK; Sundaram R; Rawale S; Liner A; Galloway DR; Kaumaya PT
J Pept Res; 2005 Feb; 65(2):189-99. PubMed ID: 15705163
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
